- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03883594
Technology-Assisted Stepped Care Study (TASC Phase 3)
March 9, 2022 updated by: Children's Hospital Medical Center, Cincinnati
Technology Assisted Stepped Care (TASC): Phase 3
The overall goal of this project is to demonstrate the feasibility, implementation, and preliminary efficacy of a technology-assisted stepped care (TASC) adherence-promotion intervention in adolescents with asthma.
This is the third phase (Phase 3) of a three-phase project to test the preliminary efficacy of a technology-assisted stepped care (TASC) intervention.
In Phase 1, we developed the intervention using patient and provider feedback from focus groups.
In Phase 2 we refined the developed intervention by having five adolescents from the focus groups test the intervention for feasibility.
In this third phase, we will enroll up to 50 adolescents to pilot-test the refined intervention for preliminary efficacy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Up to fifty adolescents with asthma will be enrolled in an open label pilot trial of the TASC adherence-promotion intervention for a duration of twelve months.
First, participants will complete baseline questionnaires related to demographic, and clinical predictors of adherence and asthma and a 4 week run-in phase to assess baseline adherence using electronic inhaler monitoring with a cellphone that is provided to them.
Following the run-in period, all participants will receive Step 1 of the TASC intervention for a minimum of 4 weeks.
Step 1 (Information) will include electronic educational information related to asthma symptoms and triggers, attacks, self-monitoring, treatments, action plans, and automated text message medication reminders.
Following the initial four weeks of Step 1, adherence will be evaluated and a rate of less than 68% will serve as the cause for "stepping up" to the next level of the intervention.
Adherence checks will continue to occur every four weeks for the duration of the study and adherence <68% will prompt movement from one level of treatment to the next.
Participants may remain at a treatment level for more than four weeks and may complete 1, 2, or 3 interventions steps during the 5 month study depending on the adolescent's adherence.
Step 2 (Motivation) will include electronic monitoring of adherence and personally tailored feedback via text messages.
Adolescents will be given access to the adherence tracking cellphone app and graphs of their inhaler adherence.
Adolescents will also receive brief, personalized text messages that provide supportive motivation and directive, tangible actions.
Step 3 (Behavioral) will include problem-solving telehealth intervention with a trained clinician.
Four telehealth sessions individually tailored to the unique needs and barriers of the adolescent will be provided.
The primary outcome measure will be electronically-monitored adherence assessed at post-treatment.
Secondary outcomes include asthma severity as well as process evaluation questions and quantitative measures of feasibility, acceptability, and satisfaction to demonstrate implementation.
Participants will remain in the study for an additional 7 months after they complete month 5 of the study.
For the remaining 7 months, participants will be randomized to one of two booster session patterns with the goal to improve inhaler adherence.
The statistician will make the randomization schedule and the principle investigator will maintain the randomization schedule.
Two different booster patterns are being used to test which pattern will be most effective.
The first booster session pattern will include booster sessions at the end of month 6, 8, and 12.
The second booster session pattern will include booster sessions at the end of month 6, 7, 8, 10, and 12. Booster sessions will review content provided during the intervention and the intervention delivery method will be consistent with the participants final intervention step.
Participants will also continue to complete monthly check-ins with the study coordinator to complete the Composite Asthma Severity Index, the Asthma Control Test, and a spirometry test.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Medical Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient age between 12-18 years
- Patient is diagnosed with severe-persistent or moderate-persistent asthma per NAEPP asthma guidelines
- Patient is prescribed at least one daily inhaled controller medication or a daily combination inhaled corticosteroid and long-acting beta-agonist and a beta-agonist bronchodilator
- English fluency for patient, caregiver, and clinician
Exclusion Criteria:
- Significant cognitive deficits that may interfere with comprehension per medical team or chart review.
- Diagnosis of serious mental illness (e.g., schizophrenia)
- Diagnosis of pervasive developmental disorder
- Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis)
- Patient receives school administered daily controller medication at the time of the enrollment visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TASC Intervention
All participants receive Step 1 of the intervention.
Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
|
Step 1 of the intervention includes educational materials related to asthma.
Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant.
Step 3 includes problem solving telehealth sessions with a trained clinician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electronic Monitoring
Time Frame: 12 months
|
The Propeller Health monitoring system includes a Bluetooth enabled sensor that attaches to the patient's inhaler.
This sensor records every dose, or "puff", the patient takes and sends it to a corresponding online database that is accessible to study staff.
Participants will be given this sensor at baseline.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility/Acceptability Questionnaire
Time Frame: 5 months
|
A 5-31 item measure of format, content, length, skills and acceptability of the intervention will be given to participants in the form of a questionnaire at the end of each step and the end of the study.
The feasibility section is on a scale of 0 to 4, 0 being the worst and 4 being the best.
The acceptability questionnaire is on a scale from 'Not at all' to 'Very,' 'Not at all' being the worst and 'Very' being the best.
|
5 months
|
System Usability Scale
Time Frame: 5 months
|
A 10 item, Likert scale giving a global view of usability will be given to participants in the form of a questionnaire at the end of each step and at the end of the study.
The scale ranges from 'Strongly Disagree' to 'Strongly Agree, with half of the items reverse scored.
|
5 months
|
Lung Function Assessment
Time Frame: Baseline assessment and then once a month for 12 months
|
The mobile spirometer records multiple parameters of the patient's lung function including forced expiratory volume, peak expiratory flow, forced vital capacity, and forced expiratory flow.
The spirometer sends the values to the corresponding mobile phone application, Propeller Health, which is directly accessible to the patient.
|
Baseline assessment and then once a month for 12 months
|
Composite Asthma Severity Index (CASI)
Time Frame: Baseline assessment and then once a month for 12 months
|
The participants' composite asthma severity index score will be calculated through the TreatSmart program.
TreatSmart will be used to determine the participant's symptom burden, health care utilization, systemic corticosteroid use, and current medication use to determine the level of asthma severity/control the participant has.
The program also makes an initial treatment recommendation based on the National Asthma Education and Prevention Program (NAEPP asthma guidelines).
Individuals are placed in Step 1 through Step 6 depending on the strength and frequency of their inhaled corticosteroid (1 being low dose and 6 being a high dose).
In addition, individuals are categorized as very poorly controlled, not well controlled, or well controlled based on how frequently they have had asthma symptoms or used their rescue inhaler, gone to the hospital or urgent care, or received steroids for asthma symptoms.
|
Baseline assessment and then once a month for 12 months
|
Asthma Control Test (ACT)
Time Frame: Baseline assessment and then once a month for 12 months
|
The ACT will be used as a measure of disease severity in this study.
The ACT is a 5-question scoring tool designed for patients with asthma who are 12 years and older.
The questions ask the patient to rate their asthma severity, symptom frequency, control, and inhaler use on a scale of 1-5.
The total score is calculated by the sum of each response, which determines how well-controlled the patient's asthma is on a scale from 5-25.
|
Baseline assessment and then once a month for 12 months
|
Attendance/Participation rates
Time Frame: 12 months
|
Participation rates will be measured 3 different ways.
The first measure will be how often participants accessed the electronic material (educational materials and/or Propeller Health app), the second measure will be how many responses to directive text messaging were received, and the third measure will be attendance to the telehealth sessions.
|
12 months
|
Acceptability of Intervention Measure (AIM)
Time Frame: At 5 months
|
A 4 item measure of participants' belief that the intervention is acceptable will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Intervention Appropriateness Measure (IAM)
Time Frame: At 5 months
|
A 4 item measure of participants' perception that the intervention is appropriate will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Feasibility of Intervention Measure (FIM)
Time Frame: At 5 months
|
A 4 item measure of participants' belief that the intervention is feasible will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
Treatment Fidelity
Time Frame: 12 months
|
Treatment fidelity needed for the intervention will be assessed.
Treatment fidelity will be assessed through fidelity checklists created specifically for each intervention session.
|
12 months
|
Time Needed for Intervention
Time Frame: 12 months
|
Sessions will be timed and the number of weeks to complete the session will be tracked to determine the average length of time needed for the intervention.
|
12 months
|
Perceived Characteristics of Intervention Scale
Time Frame: At 12 months
|
19 item measure of interventionist views toward the study intervention.
|
At 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavior Assessment System for Children-Third Edition, Self-report of Personality (BASC-3-SRP-A
Time Frame: Baseline assessment and at 5 months
|
The BASC-3 is a widely used, reliable (α= 0.94 - 0.96 , test-retest r= 0.81 -0.82), and valid inventory to assess emotional and behavioral symptoms in adolescents and young adults (ages 13-21).
|
Baseline assessment and at 5 months
|
Adolescent Barriers to Medication Scales (AMBS)
Time Frame: Baseline Assessment
|
The AMBS is an 18-item validated measure of perceived barriers to medication adherence in adolescents.
|
Baseline Assessment
|
Technology-based Experience of Need Satisfaction- Interface questionnaire (TENS-Interface)
Time Frame: Baseline assessment and then at 2 months
|
A 15- item measure of participant's competence, autonomy, and relatedness in using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Autonomy and Competence in Technology Adoption Questionnaire (ACTA)
Time Frame: Baseline Assessment
|
A 10-item measure of why people adopt use of a technology (i.e.
download an app, register with a website, purchase a wearable device, etc.).Participants respond to self-regulation statements on a scale of 1 to 5, 1 being 'not at all true' and 5 being 'very true.'
|
Baseline Assessment
|
Technology-based Experience of Need Satisfaction- Task questionnaire (TENS- Task)
Time Frame: Baseline assessment and then at 2 months
|
An 8-item measure of participant's competence, autonomy, and relatedness in managing their asthma using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Technology Effects on Need Satisfaction in Life (TENS- Life)
Time Frame: Baseline assessment and then at 2 months
|
The TENS-Life is a 10- item measure of the extent to which a user perceives that the use of a particular technology has had an influence on the satisfaction of basic psychological needs in their life.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
Knowledge Questionnaire
Time Frame: Baseline Assessment
|
A 13-item questionnaire assessing individual's knowledge of asthma symptoms, triggers, and medications.
Participants rate their level of agreement to each statement on a scale from 'Strongly Agree' to 'Strongly Disagree.'
This questionnaire will be completed at the baseline visit.
|
Baseline Assessment
|
Hardship Questionnaire
Time Frame: Baseline Assessment
|
A 19-item validated questionnaire assessing the financial strain of individuals within a household.
|
Baseline Assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2018
Primary Completion (Actual)
April 20, 2021
Study Completion (Actual)
April 20, 2021
Study Registration Dates
First Submitted
February 8, 2019
First Submitted That Met QC Criteria
March 19, 2019
First Posted (Actual)
March 21, 2019
Study Record Updates
Last Update Posted (Actual)
March 10, 2022
Last Update Submitted That Met QC Criteria
March 9, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- CIN001- {"TASC Phase 3"}
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Technology-assisted Stepped-care
-
Children's Hospital Medical Center, CincinnatiCompleted
-
University of WashingtonUnknownBurn Scar | Burns | ContractureUnited States
-
SK Telecom Americas, Inc.PeaceHealth LaboratoriesUnknownObesity | OverweightUnited States
-
The Fuzhou No 2 HospitalActive, not recruitingTibial FractureChina
-
Peter Lindenauer, MDBerkshire Medical CenterRecruitingChronic Obstructive Pulmonary Disease | Angina, Stable | Congestive Heart FailureUnited States
-
Seattle Children's HospitalUniversity of WashingtonCompleted
-
Children's National Research InstituteBaylor College of Medicine; National Institute of Diabetes and Digestive and... and other collaboratorsCompletedDiabetes Mellitus, Type 1
-
University of LeipzigCompleted
-
Baylor College of MedicineCompletedObsessive-Compulsive Disorder | Anxiety Disorders | Generalized Anxiety Disorder | Autism Spectrum Disorder | Social Anxiety Disorder | Specific Phobia | Cognitive Behavioral TherapyUnited States
-
VA Office of Research and DevelopmentNortheastern UniversityCompletedCOPD | CHFUnited States